Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effect of Manual Chest Wall Vibration on Respiratory Function and Chest Tube Duration After Thoracic Surgery

NCT07549555 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-10-01
Last updated
2026-04-24

Condition(s) studied

Thoracic Diseases

Investigational drug(s) / intervention(s)

Chest Wall OscillationConventional Control

Chest Wall Oscillation: Manual chest wall vibration is applied with the patient in a semi-Fowler's position during the expiratory phase of breathing. The practitioner places both hands flat on the chest wall and delivers gentle, rhythmic vibrations, starting from the lower lobes and progressing toward the upper lobes. Patients are instructed to inhale slowly through the nose and exhale using a pursed-lip breathing technique with a 1:2 inspiration-expiration ratio. The procedure is performed for approximately 5 minutes, corresponding to about 10 respiratory cycles, and is typically applied during the patient's rest period following routine care.

Conventional Control: Control group patients were informed about the study and provided written consent. They received only routine nursing care, with no additional interventions applied. Baseline measurements were taken at 0 minutes, including dyspnea (MBS), pain (VNRS), vital signs, and arterial blood gas values. Following routine care, the same parameters were reassessed at 3, 5, and 10 minutes and recorded. No manual chest wall vibration was performed; only standard clinical monitoring was maintained. The same assessment protocol was repeated in the evening session.

Study summary

This study was conducted to determine the effects of a manual vibration technique applied to the chest wall on the duration of chest tube placement, secretion clearance, and hemodynamic parameters in patients with chest tubes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Having undergone thoracic surgery * Having a chest tube in the postoperative period * Being hemodynamically stable * Agreeing to participate in the study * Being open to communication and cooperation Exclusion Criteria: * Severe cardiac instability * Patients unable to tolerate the procedure due to neurological or cognitive impairment * Clinical conditions that would prevent the application of vibration to the chest wall * Patients diagnosed with pneumonia * Patients with a newly implanted transvenous or subcutaneous pacemaker

Primary outcome measure(s)

  • Patient Follow-Up Form — 1 day
    Changes in respiratory and hemodynamic parameters (including respiratory rate, peripheral oxygen saturation, heart rate, blood pressure), dyspnea severity (Modified Borg Scale), and pain intensity (Visual Numeric Rating Scale) measured before the intervention and at 0, 1, 5, 10, and 15 minutes after the intervention.

Trial sites (1)

FacilityCityRegionStatus
Institute of Health Sciences, Saglik Bilimleri University Istanbul Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07549555 on ClinicalTrials.gov ↗ ← All trials in Turkey